TY - JOUR
T1 - The incidence rate of lymphadenitis after Bacille Calmette-Guérin (BCG) vaccination
AU - BCG Lymphadenitis Survey Committee
AU - Kim, Jaehong
AU - Lee, Kyujin
AU - Kim, Jong Hyun
AU - Kim, Seong Joon
AU - Lee, Soo Young
AU - Lee, Hye Jin
AU - Cho, Kyung Soon
AU - Kwon, Young Joo
AU - Lee, Byoung Chan
AU - Jo, Sang Min
AU - Ha, Jeong Hun
AU - Lee, Yoon Kyung
AU - Seung, So Jin
N1 - Publisher Copyright:
© 2016, The Korean Society of Pediatric Infectious Diseases, All rights reserved.
PY - 2016
Y1 - 2016
N2 - Purpose: Bacille Calmette-Guérin (BCG) lymphadenitis is a relatively frequent local adverse reactions after BCG vaccination. Its incidence rate is usually <1%. However, this rate may be different according to BCG strain, vaccination method or skill, etc. In the Republic of Korea, two BCG strains are used: intradermal Danish-1331 or percutaneous Tokyo-172. We surveyed the incidence rates of BCG lymphadenitis. Methods: This survey was performed in total 25 centers (5 general hospitals, 20 private pediatric clinics). Immunized type of BCG strain in study subjects was verified by directly observing the scar. The occurrence of BCG lymphadenitis was asked to their parent. In cases of BCG lymphadenitis, location, diameter size, progression of suppuration, and treatment method were investigated, as well. Results: The total number of study subjects was 3,342. Among these, the subjects suitable for enrollment criteria (total 3,222; Tokyo strain 2,501, Danish strain 721) were analyzed. BCG lymphadenitis regardless of its size developed in each five of subjects per strains, therefore, its incidence rate was 0.20% in Tokyo and 0.69% in Danish strain, respectively (P =0.086). However, when applying the WHO criteria - the development of lymph node swelling with diameter 1.5 cm or more, the incidence rate of BCG lymphadenitis was 0.16% (4 cases) in Tokyo and 0.42% (3 cases) in Danish strain, respectively. Conclusions: The incidence rate of lymphadenitis in two BCG types, percutaneous Tokyo and intradermal Danish strain BCG, is 0.20% and 0.69%, respectively. Both rates are acceptable.
AB - Purpose: Bacille Calmette-Guérin (BCG) lymphadenitis is a relatively frequent local adverse reactions after BCG vaccination. Its incidence rate is usually <1%. However, this rate may be different according to BCG strain, vaccination method or skill, etc. In the Republic of Korea, two BCG strains are used: intradermal Danish-1331 or percutaneous Tokyo-172. We surveyed the incidence rates of BCG lymphadenitis. Methods: This survey was performed in total 25 centers (5 general hospitals, 20 private pediatric clinics). Immunized type of BCG strain in study subjects was verified by directly observing the scar. The occurrence of BCG lymphadenitis was asked to their parent. In cases of BCG lymphadenitis, location, diameter size, progression of suppuration, and treatment method were investigated, as well. Results: The total number of study subjects was 3,342. Among these, the subjects suitable for enrollment criteria (total 3,222; Tokyo strain 2,501, Danish strain 721) were analyzed. BCG lymphadenitis regardless of its size developed in each five of subjects per strains, therefore, its incidence rate was 0.20% in Tokyo and 0.69% in Danish strain, respectively (P =0.086). However, when applying the WHO criteria - the development of lymph node swelling with diameter 1.5 cm or more, the incidence rate of BCG lymphadenitis was 0.16% (4 cases) in Tokyo and 0.42% (3 cases) in Danish strain, respectively. Conclusions: The incidence rate of lymphadenitis in two BCG types, percutaneous Tokyo and intradermal Danish strain BCG, is 0.20% and 0.69%, respectively. Both rates are acceptable.
KW - Adverse reaction
KW - Bacille Calmette Guerin (BCG)
KW - Dannish strain
KW - Lymphadenitis
KW - Tokyo strain
UR - https://www.scopus.com/pages/publications/85018269171
U2 - 10.14776/piv.2016.23.1.54
DO - 10.14776/piv.2016.23.1.54
M3 - Article
AN - SCOPUS:85018269171
SN - 2384-1079
VL - 23
SP - 54
EP - 61
JO - Pediatric Infection and Vaccine
JF - Pediatric Infection and Vaccine
IS - 1
ER -